FreeCurrencyRates.com

इंडियन आवाज़     29 Jan 2022 04:47:22      انڈین آواز

COVAXIN Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

  • Booster dose of vaccine, COVAXIN® (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization assay
  • 100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant
  • These data add to the body of evidence that the broad-spectrum mechanism of action of a whole virus inactivated COVID-19 vaccine, like COVAXIN® (BBV152), is a viable option in this continuously evolving pandemic

Hyderabad, India, January 12, 2022 – Bharat Biotech, today announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of COVAXIN® (BBV152) six months after getting a primary two-dose series of COVAXIN® (BBV152), neutralized the SARS-CoV-2 Omicron and Delta variants. Earlier studies demonstrated the neutralizing potential of COVAXIN® (BBV152) against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa.

The study will be published on the pre-print server, medRXiv,  shortly.

Sera samples from individuals who received a booster of COVAXIN® (BBV152) were observed to be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay. The neutralization activity of COVAXIN®-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant. More than 90% of all individuals boosted with COVAXIN® (BBV152) showed neutralizing antibodies. All participants received an initial two-dose schedule of COVAXIN® (BBV152) at Day 0 and Day 28.

“As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern,” said Mehul Suthar, Ph.D., Assistant Professor, Emory Vaccine Center and who led the laboratory analysis. “Data from this preliminary analysis show individuals receiving a booster dose of COVAXIN® have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations.”

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “We are in a continuous state of innovation and product development for COVAXIN®. The positive neutralization responses against the Omicron and Delta variants, validates our hypothesis of a multi-epitope vaccine generating both humoral and cell mediated immune responses. Our goals of developing a global vaccine against COVID-19 have been achieved with the use of COVAXIN® as a universal vaccine for adults and children.”

“The global impact of Omicron shows us that the fight against COVID-19 continues, and we’re encouraged that these data demonstrate the value of COVAXIN® as a primary and booster vaccine,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc. “These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations.”

COVAXIN® is formulated uniquely such that the same dosage can be administered to adults and children alike. COVAXIN® is a ready-to-use, liquid vaccine, stored at 2 – 8°C, with 12 months shelf life and multi-dose vial policy. The same doses of vaccine can also be used for two-dose primary immunization in adults and children and for booster dose vaccinations, making it truly a universal vaccine.

About the study

In order to evaluate the effectiveness of COVAXIN® (BBV152) against the Omicron variant, Ocugen contracted with the Emory Vaccine Center (Atlanta, GA) to test human immune sera obtained from participants (n=13) in an ongoing Phase 2 clinical trial (ClinicalTrials.gov: NCT04471519). Sera was collected 28-days post booster – six months following the primary two-dose series. Each sera was tested in a neutralization assay. Following three doses, the FRNT50 geometric mean titers (GMTs) of neutralizing antibodies against the Omicron variant measured in the samples was 75, compared to 480 against the Delta variant and 706 against the vaccine strain, D614G.

PRESS RELEASE

Leave a Reply

Your email address will not be published. Required fields are marked *

SPORTS

Manpreet Singh to lead 20-member Indian for FIH Pro League matches in South Africa

Harpal Singh Bedi New Delhi, 27 January : Versatile mid fielder Manpreet Singh will lead 20-member Indian H ...

UP Polls: SP releases list of 56 candidates; BSP releases list of 53 candidates

AMN The Samajwadi Party has released a list of 56 candidates for the Assembly elections in Uttar Pradesh to ...

Two-time Olympian and Gold medal winner Charanjit Singh is no more

Harpal Singh Bedi New Delhi, 27 January : Charanjit Singh who led India to a historic Gold Medal in 19 ...

خبرنامہ

ہندوستان میں کورونا کے دوران غریبوں کی تعداد دو گنی لیکن 40ارب پتیوں کا اضافہ

جاوید اخترعالمی ادارے آکسفیم کی رپورٹ کے مطابق کورونا وائرس ...

بھارت مخالف فرضی خبریں پھیلانے پر 35 یوٹیوب چینل، 2 ویب سائٹ بلاک

پاکستان کی مالی اعانت سے چلنے والی فرضی خبروں کے نیٹ ورک بلاک ...

نسلی امتیاز کے خلاف طاقتور آواز، ڈیسمنڈ ٹوٹو کا انتقال

جنوبی افريقہ کا ’اخلاقی پیمانہ‘ قرار دیے جانے والے نوبل انع ...

MARQUEE

National Tourism Day being celebrated

Tourism AMN National Tourism Day is being celebrated today. The day is observed on the 25th of January e ...

Tourists thrilled as Shimla gets mild snowfall

Shimla Himachal Pradesh capital and one of the favourite tourists destination Shimla on Saturday received a ...

@Powered By: Logicsart